{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:02:10Z","timestamp":1767142930316,"version":"build-2238731810"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40264-022-01217-9","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T12:02:50Z","timestamp":1659614570000},"page":"1003-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-1149","authenticated-orcid":false,"given":"Samantha","family":"Lane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"1217_CR1","unstructured":"European Medicines Agency. Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant])\u2014COVID-19 Vaccine AstraZeneca (Other viral vaccines). Pharmacovigilance Risk Assessment Committee; 2021. Report No.: EMA\/PRAC\/157045\/2021."},{"key":"1217_CR2","unstructured":"AstraZeneca UK Limited. COVID-19 Vaccine (Temporary Authorisation\u2014Review Product Information tab before reading). 2021. https:\/\/www.medicines.org.uk\/emc\/product\/12333\/smpc. Accessed 13 Sep 2021."},{"key":"1217_CR3","unstructured":"British Society for Haematology, Pavord S, Lester W, Makris M, Scully M, Hunt B. Guidance from the Expert Haematology Panel (EHP) on Covid-19 Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT). Updated Guidance on Management. Version 2.2 2021. 2021. https:\/\/b-s-h.org.uk\/media\/20075\/guidance-version-22-20210903.pdf. Accessed 31 Aug 2021."},{"issue":"22","key":"1217_CR4","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New Engl J Med. 2021;384(22):2092\u2013101. https:\/\/doi.org\/10.1056\/NEJMoa2104840.","journal-title":"New Engl J Med"},{"key":"1217_CR5","unstructured":"Public Health England. JCVI advises on COVID-19 vaccine for people aged under 40 [press release]. 2021. Accessed 7 May 2021."},{"key":"1217_CR6","unstructured":"Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine\u2014weekly summary of Yellow Card reporting. 2021. https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting."},{"key":"1217_CR7","unstructured":"RT Chen, S Black. Updated Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with Thrombocytopenia Syndrome (TTS). 2021. https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2021\/05\/TTS-Interim-Case-Definition-v10.16.3-May-23-2021.pdf. Accessed 18 May 2021."},{"key":"1217_CR8","unstructured":"Chen RT, Buttery Monash J. Updated Brighton Collaboration Case Definition for Thrombosis with Thrombocytopenia Syndrome (TTS) 2021 [updated 11 November 2021]. Available at: https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2021\/11\/TTS-Updated-Brighton-Collaboration-Case-Defintion-Draft-Nov-11-2021.pdf."},{"key":"1217_CR9","unstructured":"World Health Organization. Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). Pharmacovigilance; 2021. Report No.: WHO\/2019-nCoV\/TTS\/2021.1."},{"issue":"2","key":"1217_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1053\/j.seminhematol.2022.02.002","volume":"59","author":"M Pai","year":"2022","unstructured":"Pai M. Epidemiology of VITT. Semin Hematol. 2022;59(2):72\u20135.","journal-title":"Semin Hematol"},{"key":"1217_CR11","unstructured":"Chan BT, Bobos P, Odutayo A, Pai M. Meta-analysis of risk of vaccine-induced immune thrombotic thrombocytopenia following ChAdOx1-S recombinant vaccine. medRxiv. 2021:2021.05.04.21256613. 2022. https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2021\/05\/08\/2021.05.04.21256613.full.pdf."},{"key":"1217_CR12","unstructured":"Department of Health and Social Care. Use of the AstraZeneca COVID-19 (AZD1222) vaccine: updated JCVI statement. 2021. https:\/\/www.gov.uk\/government\/publications\/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement-7-may-2021\/use-of-the-astrazeneca-covid-19-azd1222-vaccine-updated-jcvi-statement-7-may-2021. Accessed 7 May 2021."},{"issue":"5","key":"1217_CR13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/pds.4197","volume":"26","author":"C Renoux","year":"2017","unstructured":"Renoux C, Dell\u2019Aniello S, Brenner B, Suissa S. Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism. Pharmacoepidemiol Drug Saf. 2017;26(5):554\u201360.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1217_CR14","unstructured":"UK Health Security Agency. COVID-19 vaccination programme Information for healthcare practitioners. Version 3.11. 2021. Accessed 21 Dec 2021."},{"key":"1217_CR15","unstructured":"World Health Organization, UNICEF. COVID-19 vaccination: supply and logistics guidance. Geneva: World Health Organization. 2021."},{"issue":"2","key":"1217_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40264-021-01138-z","volume":"45","author":"RE Ferner","year":"2022","unstructured":"Ferner RE, Stevens RJ, Anton C, Aronson JK. Spontaneous reporting to regulatory authorities of suspected adverse drug reactions to COVID-19 vaccines over time: the effect of publicity. Drug Saf. 2022;45(2):137\u201344.","journal-title":"Drug Saf"}],"updated-by":[{"DOI":"10.1007\/s40264-022-01233-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000}}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01217-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01217-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01217-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T09:42:50Z","timestamp":1662198170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01217-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1217"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01217-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"19 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40264-022-01233-9","URL":"https:\/\/doi.org\/10.1007\/s40264-022-01233-9","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Drug Safety Research Unit (DSRU) receives donations and grants from pharmaceutical companies; however, the companies have no control over the conduct or publication of its studies. The DSRU has received grants to conduct unconditional studies on the Oxford\/AstraZeneca COVID-19 vaccine and for conducting Clinical Practice Research Datalink (CPRD) studies for Pfizer, Moderna, and Janssen COVID-19 vaccines. The DSRU has conducted benefit\u2013risk studies on products for COVID-19, including remdesivir, lopinavir\/ritonavir, chloroquine and hydroxychloroquine, and convalescent plasma. Professor Shakir is the principal investigator for an active surveillance study for the Oxford\/AstraZeneca vaccine, but this assessment is unrelated to this study. Professor Shakir has been a member of Data Safety Monitoring Boards for Ipsen, Biogen, and Diurnal. None of these companies have any involvement with COVID-19 vaccines. Professor Shakir was also invited by AstraZeneca to advise on the events of thrombosis with thrombocytopenia with the COVID-19 vaccine and to be a member of an advisory committee on a safety study of the Oxford\/AstraZeneca vaccine in Europe. Samantha Lane has no conflicts of interest with regard to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No external funding was received for the completion of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"No additional data are available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Patients and the public were not consulted during the course of this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"Ethics approval was not required for this research due to the nature of the data source.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Samantha Lane was responsible for data acquisition, analyses, and interpretation. Samantha Lane and Saad Shakir were responsible for study conception, drafting and reviewing the manuscript, and approval of the final version for publication.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}